Long term follow-up of Asian patients with chronic myeloid leukemia (CML) receiving allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-identical sibling - Evaluation of risks and benefits

Annals of Hematology

Volumn 83, Issue 5, 2004, Pages 286-294

  Koh, L P ^a   Hwang, W Y K ^a   Tan, C H ^a   Linn, Y C ^a   Goh, Y T ^a   Chuah, C T H ^a   Ng, H J ^a   Fook Chong, S M C ^a   Tan, P H C ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Allogeneic transplant; Blast crisis; Chronic myeloid leukemia; Chronic phase; Graft versus host disease; Matched sibling

Indexed keywords

ALPHA INTERFERON; AMPHOTERICIN B; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMATINIB; IMMUNOGLOBULIN; ITRACONAZOLE; METHOTREXATE; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASIAN; BONE MARROW EXAMINATION; CANCER PATIENT; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG RESPONSE; FEMALE; FEMALE STERILITY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HYPOTHYROIDISM; INCIDENCE; KAPLAN MEIER METHOD; LIVING DONOR; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MALE STERILITY; MULTIVARIATE ANALYSIS; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RECIPIENT; RISK BENEFIT ANALYSIS; SIBLING; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CAUSE OF DEATH; CHILD; CHILD, PRESCHOOL; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, CHRONIC; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 2342620716     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0810-2     Document Type: Article

References (38)

1. Barrett J, Childs R (2000) Non-myeloablative stem cell transplants. Br J Haematol 111:6-17
2. Blazar BR, Orr HT, Arthur DC, Kersey JH, Fillipovich AH (1985) Restriction fragment length polymorphism as markers of engraftment in allogeneic marrow transplantation. Blood 66:1436-1444
3. Bortin MM, Horowitz MM, Rimm AA (1992) Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 10:113-122
4. Cervantes F, Robertson JE, Rozman C, Baccarani M, Tura S, Gomez GA, Braun TJ, Clarkson BD, Pereira A (1994) Long-term survivors in chronic granulocytic leukaemia: a study by the International CGL Prognosis Study Group. Italian Cooperative CML Study Group. Br J Haematol 87:293-300
5. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P (2000) Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18-29
6. Clift RA, Anasetti C (1997) Allografting for chronic myeloid leukaemia. Baillieres Clin Haematol 10:319-336
7. Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E, Deeg HJ, Doney KC, Fisher LD, Hansen JA, McDonald GB, Sanders JE, Schoch G, Storb R, Sullivan KM, Witherspoon RP, Appelbaum FR (1994) Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 84:2036-2043
8. Copelan EA, Penza SL, Theil KS, Elder PJ, Bechtel TP, Tighe MB, Ezzone SA, Scholl MD, Belt PS, Young DC, Avalos BR (2000) The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplant 26:1037-1043
9. Copelan EA, Penza SL (1999) Preparative regimens for stem cell transplantation. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds) Hematology. Basic principles and practice, 3rd edn. Churchill Livingstone, New York, pp 1628-1642
10. Cox DR (1972) Regression models and life tables. J R Stat Med 34:187-220
11. Devergie A, Blaise D, Attal M, Tigaud JD, Jouet JP, Vernant JP, Bordigoni P, Ifrah N, Dauriac C, Cahn JY, et al. (1995) Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood. 85:2263-2268
12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:1031-1037
13. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 1038-1042
14. Enright H, Daniels K, Arthur DC, Dusenbery KE, Kersey JH, Kim T, Miller WJ, Ramsay NK, Vercellotti GM, Weisdorf DJ, McGlave PB (1996) Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. Bone Marrow Transplant 17:537-542
15. Goldman JM, Druker BJ (2001) Chronic myeloid leukemia: current treatment options. Blood. 98:2039-2042
16. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, et al. (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235-2238
17. Gratwohl A, Herman J, Goldman JM, Arcese W, Devergie A, Frassoni F, Gahrton G, Kolb HJ, Niederwieser D, Ruutu T, Vernant JP, de Witte T, Apperley J (1998) Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352:1087-1092
18. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA, Petersdorf EW, Radich J, Sanders JE, Storb RF, Sullivan M Anasetti C (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 338:962-968
19. Horowitz MM, Rowlings PA, Passweg JR (1996) Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 17 [Suppl 3]:S5-S6
20. Kantarjian HM, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Faderl S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M (2002) Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 99:3547-3553
21. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652
22. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
23. Koh LP, Hwang WYK, Chuah CTH, Linn YC, Goh YT, Ng HJ, PHC Tan (2003) Imatinib mesylate (STI-571) given concurrently with non-myeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis. Bone Marrow Transplant. 31:305-308
24. Lee CK, Lie AK, Liang R, Au WY, Chen FE, Chim CS, Kwong YL (1999) Outcome of Chinese patients with chronic myeloid leukaemia (CML) underwent allogeneic bone-marrow transplantation (BMT). Am J Hematol 61:85-89
25. Mantel N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170
26. Nowell P, Hungerford D (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497
27. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004
28. Ong YW, Tan P, Lim SH, Ng HW, Gob YT (1990) Bone marrow transplantation for treatment chronic myelogenous leukemia (CML) - preliminary experience in Singapore. Ann Acad Med Singapore 19:169-174
29. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Non-myeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441-445
30. Passweg J, Walker I, Sobocinski K, Rio B, Litzow M, Giralt S, Carreras E, Szydlo R, Bolwell B, Ilhan O, Seiter K, Maharaj D, Pasquini R, Carabasi M, Kolb H, Gale R, Schouter H, Cornelissen J, Goldman J, Gratwohl A, Klein J, Horowitz M (2001) Validation of EBMT risk score for recipients of allogeneic hematopoietic stem cell transplants for chronic myelogenous leukemia (CML) (abstract). Blood 98:349a
31. Przepiorka D, Weisdorf D, Martin P, Mingemann HG, Beatty P, Hows J, Thomas ED (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828
32. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-3539
33. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330-1340
34. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, et al. (1986) Methotrexate and cyclosporine compared with cyclosporin alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 31:729-735
35. Sullivan KM, Agura E, Anasetti C, Appelbaum F, Badger C, Bearman S, Erickson K, Flowers M, Hansen J, Loughran T, et al. (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250-259
36. Sullivan KM (1999) Graft-versus-host disease. In: Thomas ED, Blume KG, Forman SJ (eds) Hematopoietic cell transplantation, 2nd edn. Blackwell Science, Boston, pp 515-536
37. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, et al. (1986) Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 104:155-163
38. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, Olavarria E, Kanfer E, Goldman JM (2002) Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 99:2304-2309